Brittle bone disease or osteogenesis imperfecta is a disease of defective collagen- induced inadequate bony matrix, weak bones, frequent and numerous fractures, progressive deformities of limbs and spine, retarded growth and short stature. Induce differentiation of tissue-derived mesenchymal stem cell pursue treatment of Osteogenesis imperfecta. This paper addresses critical review over the drugs that have an ability to differentiate bone marrow stem cell as well present effects of drugs on the said disease. The author conducted on extensive review of published literature on stem cells using general search engines and meta search engines through two key search strategies; medical subject heading (mesh) and text word searching. Once the ‘key article’ was identified, authors used the ‘related article’ features and further reference list harvesting. As series of research suggest that steroid, dexamethasone, statin like Imatinib mesylate, Desatinib and zoledronic acid are effective drugs for stem cell differentiation by varying mechanism. In conclusion author can say that the embryonic stem cell therapy has a lot of ethical dilemma because of its source as embryo. Better option is to use adult stem cell and increase its differentiation by using natural drug which is more cost effective, having low side effect and solves related ethical concerns as well. Also author advocate in concentrating further researches and funding in this field more on finding natural drug which can give good adult stem cell differentiation like to be embryonic so that society can be served with global acceptance.